ADDC - AstraZeneca Collaboration

Areas Of Interest
Cardiovascular & Metabolic Disease (CVMD)
  • Heart failure and cardiac regeneration
  • Diabetic islet cell health, insulin sensitisation, and the return of beta cell function
  • Nephropathy
  • Dyslipidaemia, atherosclerosis and chronic heart disease
  • NASH (non-alcoholic steato hepatitis)
  • Chronic kidney disease and diabetic nephropathy
Respiratory, Inflammation & Autoimmune (RIA)
  • Asthma
  • COPD
  • Idiopathic pulmonary fibrosis
  • Rheumatology focus in areas such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis and gout
  • Opportunistic interest in co-morbidities or adjacent diseases to the above with similar prescriber bases
  • Lung cancer
  • Haematological malignancies
  • Breast cancer
  • Ovarian cancer
  • Immune mediated therapies
  • Genetic and molecular targeting
  • DNA damage repair
  • Antibody-drug conjugates
  • Biologically-synergistic combinations
  • Neurodegenerative disorders
  • Neurodevelopmental disorders
  • Chronic analgesia
  • Serious bacterial infections
  • Respiratory viruses
Personalised Healthcare (PHC)
  • Methodology for patient Selection
  • Disease Identification
  • Pharmacological Assessment
  • Predictive safety and predictive efficacy platforms
  • Target validation tools and technologies
  • Novel HTS/lead generation approaches
  • Novel chemical libraries with evidence of biological relevance
  • Stem cell biology
  • Novel technologies for antibodies and vaccines
Time Line
Fall 2015
Now accepting submissions for 2015. Deadline October 15th, 2015.
Fall 2015
Results anticipated November, 2015